Skip to main content
      RT @KDAO2011: Sentinel joint! #POS0385
      Study of 524 preclinical RA followed 2 yrs found that intermetatarsal bursitis (I

      k dao KDAO2011

      4 years 5 months ago
      Sentinel joint! #POS0385 Study of 524 preclinical RA followed 2 yrs found that intermetatarsal bursitis (IMB) can predict devl't of RA esp in ACPA+ pts 👉>70% w/abnormal IMB dev RA over 1 yr 👉synovial lining is found in the intermetatarsals #EULAR2021 @rheumnow https://t.co/RQzZRh1eC2
      RT @drdavidliew: Do you think that JAK1 selectivity matters in rheumatological clinical practice?#EULAR2021 @RheumNow

      David Liew drdavidliew

      4 years 5 months ago

      Do you think that JAK1 selectivity matters in rheumatological clinical practice? #EULAR2021 @RheumNow

      RT @Janetbirdope: Does vit D level predict response to RA Rx? Yes...maybe! POS0100 showed in 236 RA pts, 57% starting TN

      Janet Pope Janetbirdope

      4 years 5 months ago
      Does vit D level predict response to RA Rx? Yes...maybe! POS0100 showed in 236 RA pts, 57% starting TNFi, rest other bDMARDs, at 1 yr, good responders & remission 4x less likely to respond if low vit D but sig for DAS(ESR) not CDAI/SDAI. ?Give VIT D to all! #EULAR2021 @RheumNow
      RT @uptoTate: "PsA is the most common co-morbidity in pediatric PsO patients (OR - 5.3), the second is obesity." Dr. Yon

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      "PsA is the most common co-morbidity in pediatric PsO patients (OR - 5.3), the second is obesity." Dr. Yonathan Butbul. It is estimated that 1/3 of PsO pts will have juvenile disease onset, but may not be diagnosed until adulthood. #EULAR2021 @RheumNow
      Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
      RT @Nellziade: Guselkumab in patients with active #Psoriatic_Arthritis & who failed anti-TNF: COSMOS study Phase 3b

      Nelly ZIADE 🍀 Nellziade

      4 years 5 months ago
      Guselkumab in patients with active #Psoriatic_Arthritis & who failed anti-TNF: COSMOS study Phase 3b A new option for the difficult-to-treat patients with PsA @DrLauraCoates #EULAR2021 https://t.co/2aOqZYfbsT
      RT @Nellziade: Upacitinib in #Psoriatic_Arthritis with axial manifestations
      Post hoc analysis from SELECT PsA1/2
      #EULAR2

      Nelly ZIADE 🍀 Nellziade

      4 years 5 months ago
      Upacitinib in #Psoriatic_Arthritis with axial manifestations Post hoc analysis from SELECT PsA1/2 #EULAR2021 @deodhara https://t.co/867c2J3DiI
      The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 
      The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
      On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody
      RT @EMEUNET: Very interesting 🤔 talk about the role of #comorbidities in difficult to treat #RA by our fabulous #emeu

      EMEUNET EMEUNET

      4 years 5 months ago
      Very interesting 🤔 talk about the role of #comorbidities in difficult to treat #RA by our fabulous #emeunet past chair @ElenaNikiUK at #EULAR2021 @eular_org https://t.co/zyQ0DkKhbu
      RT @TheLancetRheum: NEW RESEARCH—Safety and efficacy of #rituximab in #SystemicSclerosis (DESIRES): a double-blind, in

      The Lancet Rheumatology TheLancetRheum

      4 years 5 months ago
      NEW RESEARCH—Safety and efficacy of #rituximab in #SystemicSclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial https://t.co/Sb3d1kPhL4 #LancetRheumatology https://t.co/4SMVGY0C3M
      RT @Yuz6Yusof: Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL40 expression in salivary gland biopsy & bloods in pSS and pSS-associated lymphoma. Future work will clarify the exact role of IL-40 as a tx target #EULAR2021 #POS0177 @RheumNow https://t.co/uXAYAlkdtD
      RT @MeralElRamahiMD: ⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN p

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago

      ⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

      RT @Yuz6Yusof: Does #baricitinib affect B-cell activity in #SLE?Dr Dorner reported in patients with dsDNA ab+ve (=>30

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Does #baricitinib affect B-cell activity in #SLE?Dr Dorner reported in patients with dsDNA ab+ve (=>30iU/mL), Bari 4mg reduced dsDNA,anti-Sm, cardiolipin and IgG at Wk24 vs placebo. In pts who dsDNA normalised, their SRI-4 was no different vs dsDNA+ #EULAR2021 #POS0686 @RheumNow https://t.co/pmNWEE9hqg
      ×